TNFRSF8 and Hodgkins lymphoma: Responses to CD30/CD3 bispecific antibodies in Hodgkin lymphoma appear modest in the absence of checkpoint blockade, and consistent with this limited single-agent activity, Genmab has recently discontinued development of GEN3017 in relapsed/refractory CD30-positive lymphomas as part of a strategic pipeline reprioritization [203].